Home
PCRX
PCRX News

Latest Pacira BioSciences Inc. (PCRX) News on November 17, 2024

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

GlobeNewswire

3 days ago

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Argus Research

5 days ago

PCRX: Lowering target price to $13.00

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

GlobeNewswire

5 days ago

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Argus Research

6 days ago

Daily – Vickers Top Insider Picks for 11/11/2024

Argus Research

9 days ago

Daily – Vickers Top Insider Picks for 11/08/2024

Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth

Zacks

10 days ago

Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth

Thomson Reuters StreetEvents

10 days ago

Q3 2024 Pacira Biosciences Inc Earnings Call

Argus Research

10 days ago

Daily – Vickers Top Insider Picks for 11/07/2024

Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ...

GuruFocus.com

10 days ago

Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ...

Associated Press Finance

11 days ago

Pacira: Q3 Earnings Snapshot

Pacira BioSciences Reports Third Quarter 2024 Financial Results

GlobeNewswire

11 days ago

Pacira BioSciences Reports Third Quarter 2024 Financial Results

Argus Research

11 days ago

Daily – Vickers Top Insider Picks for 11/06/2024

Argus Research

12 days ago

PCRX: What does Argus have to say about PCRX?

Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

12 days ago

Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Know Ahead Of Earnings

Argus Research

12 days ago

Daily – Vickers Top Insider Picks for 11/05/2024

Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings

GlobeNewswire

13 days ago

Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings

Argus Research

13 days ago

Daily – Vickers Top Insider Picks for 11/04/2024

Argus Research

16 days ago

Daily – Vickers Top Insider Picks for 11/01/2024

Argus Research

17 days ago

Daily – Vickers Top Insider Picks for 10/31/2024

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

GlobeNewswire

18 days ago

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

Argus Research

18 days ago

Daily – Vickers Top Insider Picks for 10/30/2024

Argus Research

19 days ago

Daily – Vickers Top Insider Picks for 10/29/2024

Argus Research

20 days ago

Daily – Vickers Top Insider Picks for 10/28/2024

Argus Research

23 days ago

Daily – Vickers Top Insider Picks for 10/25/2024

Argus Research

24 days ago

Daily – Vickers Top Insider Picks for 10/24/2024

Argus Research

25 days ago

Daily – Vickers Top Insider Picks for 10/23/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/22/2024

Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock?

Zacks

a month ago

Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock?

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

GlobeNewswire

a month ago

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/21/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/18/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/17/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/16/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/15/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/14/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/11/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/10/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/09/2024

Argus Research

a month ago

PCRX: Raising target price to $13.00

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/08/2024

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

a month ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/07/2024

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings

Simply Wall St.

a month ago

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/04/2024

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

GlobeNewswire

a month ago

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 10/03/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/02/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/01/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/30/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/27/2024

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

GlobeNewswire

2 months ago

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/26/2024

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders

PR Newswire

2 months ago

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/25/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/24/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/23/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/20/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/19/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/18/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/17/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/16/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/13/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/12/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/11/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/10/2024

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

2 months ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

2 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/09/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/06/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/05/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/04/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 09/03/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 08/30/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 08/29/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 08/28/2024

Argus Research

3 months ago

PCRX: Lowering target price to $12.00

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 08/27/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 08/26/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 08/23/2024

Argus Research

3 months ago

PCRX: Rating decreased to a SELL

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

GlobeNewswire

3 months ago

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks

3 months ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Pacira BioSciences, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Simply Wall St.

4 months ago

Pacira BioSciences, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues

Zacks

4 months ago

Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues

Associated Press Finance

4 months ago

Pacira: Q2 Earnings Snapshot

Pacira BioSciences Reports Second Quarter 2024 Financial Results

GlobeNewswire

4 months ago

Pacira BioSciences Reports Second Quarter 2024 Financial Results

Argus Research

4 months ago

PCRX: Lowering target price to $21.00

Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

GlobeNewswire

4 months ago

Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

Nanotechnology in medicine: Who are the leading public companies?

Medical Device Network

4 months ago

Nanotechnology in medicine: Who are the leading public companies?

Should Value Investors Buy Pacira BioSciences (PCRX) Stock?

Zacks

4 months ago

Should Value Investors Buy Pacira BioSciences (PCRX) Stock?

Argus Research

4 months ago

PCRX: What does Argus have to say about PCRX?

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

GlobeNewswire

4 months ago

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

Argus Research

4 months ago

PCRX: Lowering target price to $22.00

Argus Research

4 months ago

PCRX: Lowering target price to $24.00

Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)?

Simply Wall St.

5 months ago

Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)?

Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)

GuruFocus.com

5 months ago

Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

GlobeNewswire

6 months ago

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts

Simply Wall St.

6 months ago

Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

GlobeNewswire

6 months ago

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

GlobeNewswire

6 months ago

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

Share on Social Networks: